Impact of rpoB gene mutations and Rifampicin-resistance levels on treatment outcomes in Rifampicin-resistant tuberculosis
This study indicates that low-level rifampicin mono-resistance in tuberculosis (TB) patients is associated with poor clinical outcomes. A mutation at the Leu430Pro codon showed the highest odds ratio of 2.98 (p-value 0.0591), suggesting a potential association with rifampicin resistance that warrants further research, especially in areas with high drug-resistant TB. It highlights the need for more aggressive treatment strategies for patients with low-level rifampicin resistance, even if they seem solely mono-resistant.
Authors
- Anbazhagi Muthukumar
- Venkateswari Ramachandra
- Suganthi Palavesam
- Vijayalakshmi Jawaharlal Nehru
- Maria Jose Vadakunnel
- Subramani Sangeetha (ORCID: https://orcid.org/0000-0002-9167-1269)
- Muthuraj Muthaiah (ORCID: https://orcid.org/0000-0001-9995-1719)
- S. Springer Healthcare Italia s.r.
- Gunavathy Pradhabane
- Balasundaram Revathi Mani
- Usharani Brammacharry
- Govindarajan Soundappan
- Azger Dusthackeer VN
Institutions
- University of Madras (IN)
- Central University of Kerala (IN)
- Indian Council of Medical Research (IN)
- National Institute of Research in Tuberculosis (IN)
- Saveetha University (IN)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1186/s12879-025-10655-6
- Citations
- 12
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 16.75